

# Rebecca King

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5808907/publications.pdf>

Version: 2024-02-01

134  
papers

2,180  
citations

201575

27  
h-index

276775

41  
g-index

134  
all docs

134  
docs citations

134  
times ranked

2904  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
2	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
3	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2016, 40, 36-43.	2.1	103
4	Routine Cerebrospinal Fluid Enterovirus Polymerase Chain Reaction Testing Reduces Hospitalization and Antibiotic Use for Infants 90 Days of Age or Younger. <i>Pediatrics</i> , 2007, 120, 489-496.	1.0	87
5	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
6	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS) and the role of next-generation sequencing. <i>American Journal of Hematology</i> , 2016, 91, 492-498.	2.0	70
7	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2019, 33, 2466-2480.	3.3	66
8	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
9	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
10	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 647-665.	1.4	55
11	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. <i>American Journal of Roentgenology</i> , 2016, 206, 655-659.	1.0	54
12	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1037-1046.	2.2	46
13	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
14	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88L265P Mutations. <i>American Journal of Clinical Pathology</i> , 2016, 145, 843-851.	0.4	43
15	False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. <i>Haematologica</i> , 2019, 104, e248-e251.	1.7	43
16	Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. <i>American Journal of Clinical Pathology</i> , 2021, 155, 160-178.	0.4	42
17	Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1282-1290.	2.1	41
18	ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41

#	ARTICLE	IF	CITATIONS
19	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. <i>American Journal of Hematology</i> , 2019, 94, 291-298.	2.0	40
20	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
21	Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models. <i>Clinical Cancer Research</i> , 2005, 11, 2680-2685.	3.2	33
22	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
23	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 667-681.	1.4	33
24	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
25	Use of flow cytometry in the diagnosis of lymphoproliferative disorders in fluid specimens. <i>Diagnostic Cytopathology</i> , 2014, 42, 664-670.	0.5	31
26	A Comparative Analysis of Molecular Genetic and Conventional Cytogenetic Detection of Diagnostically Important Translocations in More Than 400 Cases of Acute Leukemia, Highlighting the Frequency of False-Negative Conventional Cytogenetics. <i>American Journal of Clinical Pathology</i> , 2011, 135, 921-928.	0.4	28
27	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
28	Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction. <i>Modern Pathology</i> , 2003, 16, 1248-1256.	2.9	27
29	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
30	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
31	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
32	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. <i>Leukemia</i> , 2016, 30, 2273-2275.	3.3	23
33	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. <i>Blood Cancer Journal</i> , 2020, 10, 5.	2.8	22
34	Hodgkin Lymphoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 12-25.	2.4	21
35	Acquired isochromosome 12p, somatic TP53 and PTEN mutations, and a germline ATM variant in an adolescent male with concurrent acute megakaryoblastic leukemia and mediastinal germ cell tumor. <i>Cancer Genetics</i> , 2014, 207, 153-159.	0.2	21
36	IgM Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2013, 140, 519-524.	0.4	19

#	ARTICLE	IF	CITATIONS
37	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021, 5, 2272-2278.	2.5	19
38	FACTORS INFLUENCING THE DECISION TO TEST YOUNG INFANTS FOR HERPES SIMPLEX VIRUS INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 1156-1158.	1.1	18
39	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
40	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	2.5	18
41	Morphologically Occult Systemic Mastocytosis in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2015, 144, 493-502.	0.4	17
42	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17
43	Atypical cutaneous $\hat{\beta}1$ T cell proliferation with morphologic features of lymphoma but with clinical features and course of <sc>PLEVA</sc> or lymphomatoid papulosis. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 1012-1017.	0.7	15
44	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	0.6	15
45	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14
46	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	2.0	13
47	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. <i>American Journal of Clinical Pathology</i> , 2021, 155, 179-210.	0.4	13
48	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2018, 150, 421-431.	0.4	12
49	Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2021, 155, 239-266.	0.4	12
50	Assessment of fixed-duration therapies for treatment-naïve <sc>Waldenström</sc> macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
51	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
52	Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome. <i>American Journal of Clinical Pathology</i> , 2021, 155, 211-238.	0.4	12
53	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
54	Novel t(1;8)(p31.3;q21.3) <i>NFIA</i> - <i>RUNX1T1</i> Translocation in an Infant Erythroblastic Sarcoma. <i>American Journal of Clinical Pathology</i> , 2021, 156, 129-138.	0.4	10

#	ARTICLE	IF	CITATIONS
55	Novel germline missense <i>DDX41</i> variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1337-1339.	0.6	9
56	The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 683-699.	1.4	9
57	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	0.6	9
58	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
59	Broadening the Morphologic Spectrum of <i>Bartonella henselae</i> Lymphadenitis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 342-347.	2.1	8
60	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020, 189, e104-e108.	1.2	8
61	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	1.2	8
62	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
63	Interference with the Jaffé method for creatinine following 5-aminolevulinic acid administration. <i>Photodiagnosis and Photodynamic Therapy</i> , 2010, 7, 268-274.	1.3	7
64	The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. <i>Blood Cancer Journal</i> , 2019, 9, 24.	2.8	7
65	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021, 5, 2101-2105.	2.5	7
66	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
67	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. <i>Human Pathology</i> , 2017, 64, 207-212.	1.1	6
68	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2019, 152, 277-301.	0.4	6
69	p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia. <i>Journal of Hematopathology</i> , 2021, 14, 15-22.	0.2	6
70	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 184.	2.8	6
71	CLL/SLL diagnosed in an adolescent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1107-1110.	0.8	5
72	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Bone Marrow Biopsy Operator Experience and Impact on Aspirate, Biopsy, and Ancillary Testing Quality. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 241-247.	1.2	5
74	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clinical Cancer Research, 2020, 26, 5759-5771.	3.2	5
75	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	0.6	5
76	Genetics of Diffuse Large B-Cell Lymphoma. Cancer Journal (Sudbury, Mass ), 2014, 20, 43-47.	1.0	4
77	Near-haploid B lymphoblastic leukemia with an apparent hyperdiploid karyotype: the critical role of SNP analysis in establishing proper diagnosis. Journal of Hematopathology, 2014, 7, 27-32.	0.2	4
78	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	2.8	4
79	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2018, 132, 456-456.	0.6	4
80	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. Blood, 2019, 134, 4092-4092.	0.6	4
81	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4
82	Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1633, 1-17.	0.4	3
83	Reply to Castillo et al.. American Journal of Hematology, 2018, 93, E71-E73.	2.0	3
84	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	2.8	3
85	Effects of TTI-621 (SIRP $\alpha$ ±Fc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.. Journal of Clinical Oncology, 2017, 35, 112-112.	0.8	3
86	Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.. Journal of Clinical Oncology, 2020, 38, 8550-8550.	0.8	3
87	The broad and challenging landscape of extranodal lymphoproliferations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 633-646.	1.4	2
88	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. Leukemia Research Reports, 2021, 15, 100242.	0.2	2
89	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent. Pediatric and Developmental Pathology, 2021, 24, 264-268.	0.5	2
90	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer, 2021, 60, 678-686.	1.5	2

#	ARTICLE	IF	CITATIONS
91	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
92	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
93	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
94	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
95	Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 125, 2-10.	1.1	2
96	Extracavitary primary effusion lymphoma in an HIV-positive patient with Kaposi sarcoma-associated. <i>Community Oncology</i> , 2009, 6, 523-525.	0.2	1
97	Iron-laden macrophage in autoimmune disease. <i>Blood</i> , 2014, 123, 469-469.	0.6	1
98	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, e13569-e13569.	0.8	1
99	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	0.6	1
100	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
101	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. <i>Blood</i> , 2019, 134, 4129-4129.	0.6	1
102	Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7562-7562.	0.8	1
103	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
104	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016, 128, 5592-5592.	0.6	1
105	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. <i>Blood</i> , 2018, 132, 1693-1693.	0.6	1
106	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
107	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
108	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1



#	ARTICLE	IF	CITATIONS
109	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
110	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
111	Small B-Cell Lymphomas. , 2018, , 213-270.e3.		0
112	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report. <i>Journal of Hematopathology</i> , 2021, 14, 157-162.	0.2	0
113	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
114	Epstein Barr Virusâ€“Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. <i>Kidney International Reports</i> , 2021, 6, 2223-2227.	0.4	0
115	Prognostic and therapeutic impact of cytogenetic abnormalities in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7058-7058.	0.8	0
116	Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. <i>Blood</i> , 2018, 132, 574-574.	0.6	0
117	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 4344-4344.	0.6	0
118	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0
119	WaldenstrÃ¶m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
120	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
121	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
122	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 1770-1770.	0.6	0
123	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
124	Addressing the Challenges of Eosinophilia and Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2021, 155, 156-159.	0.4	0
125	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	0.6	0
126	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	0.6	0



#	ARTICLE	IF	CITATIONS
127	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
128	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
129	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
130	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
131	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
132	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
133	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
134	Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. <i>Blood</i> , 2016, 127, 268.	0.6	0